| Kristine Marie Dixon, | |
|
1901 Tate Springs Rd, Lynchburg, VA 24501-1109 | |
| (434) 439-0981 | |
| Not Available |
| Full Name | Kristine Marie Dixon |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1901 Tate Springs Rd, Lynchburg, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881014231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0102204839 (Virginia) | Primary |
| Entity Name | Centra Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649228966 PECOS PAC ID: 4789606088 Enrollment ID: O20051230000147 |
News Archive
In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.
Using a powerful data-crunching technique, Johns Hopkins researchers have sorted out how a protein keeps defective genetic material from gumming up the cellular works. The protein, Dom34, appears to "rescue" protein-making factories called ribosomes when they get stuck obeying defective genetic instructions, the researchers report in the Feb. 27 issue of Cell.
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
An exciting collaboration between the Universities of Cambridge and Nottingham has resulted in new insights into the hypertension that frequently blights pregnancy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristine Marie Dixon, 1901 Tate Springs Rd, Lynchburg, VA 24501-1109 Ph: (434) 439-0981 | Kristine Marie Dixon, 1901 Tate Springs Rd, Lynchburg, VA 24501-1109 Ph: (434) 439-0981 |
News Archive
In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.
Using a powerful data-crunching technique, Johns Hopkins researchers have sorted out how a protein keeps defective genetic material from gumming up the cellular works. The protein, Dom34, appears to "rescue" protein-making factories called ribosomes when they get stuck obeying defective genetic instructions, the researchers report in the Feb. 27 issue of Cell.
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology.
An exciting collaboration between the Universities of Cambridge and Nottingham has resulted in new insights into the hypertension that frequently blights pregnancy.
› Verified 7 days ago
Morgan S Mandeville, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 | |
John B Arnold, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1212 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Denise L Fenton, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1212 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Robert Skyler Mccurley, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 121 Mcconville Road, Lynchburg, VA 24502 Phone: 434-237-8886 Fax: 434-239-6807 | |
Dr. Richard C Morris, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 | |
Bradley S Malcolm, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 105 Richeson Dr, Lynchburg, VA 24501 Phone: 434-385-7776 Fax: 434-385-5846 | |
Raul Barroso, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 2137 Lakeside Dr, Lynchburg, VA 24501 Phone: 434-404-7200 Fax: 434-385-8616 |